Paper Review Records
全部论文审稿周期
1 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
232
天
Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial
作者
Ying Liu; Xiangjiao Meng; Yan Yu; Jianhua Chen; Runxiang Yang; Laiyu Liu; Yanqiu Zhao; Ruifen Tian; Dianming Li; Ruiling Ning; Qingshan Li; Guowu Wu; Li Wang; Xianghui Duan; Xuejie Guo; Yan Hu; Weili Liu; Haifeng Liu展开收起
作者单位
1. Department of Oncology , Jilin Provincial Cancer Hospital , Changchun, Jilin, P. R. China .; 2. Department of Radiation Oncology, Shandong Cancer Hospital and Institute , Shandong First Medical University and Shandong Academy of Medical Sciences , Jinan, Shandong, P. R. China .; 3. Department of Thoracic Medical Oncology , The Affiliated Cancer Hospital of Harbin Medical University , Harbin, Heilongjiang, P. R. China .; 4. Department of Thoracic Medical Oncology , Hunan Provincial Cancer Hospital , Changsha, Hunan, P. R. China .; 5. Department of Medical Oncology , Yunnan Provincial Cancer Hospital , Kunming, Yunnan, P. R. China .; 6. Department of Respiratory and Critical Care Medicine , Nanfang Hospital Affiliated to Southern Medical University , Guangzhou, Guangdong, P. R. China .; 7. Department of Thoracic Medical Oncology , The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital , Zhengzhou, Henan, P. R. China .; 8. Department of Respiratory Oncology , Shanxi Provincial Cancer Hospital , Taiyuan, Shanxi, P. R. China .; 9. Department of Respiratory and Critical Care Medicine , The First Affiliated Hospital of Bengbu Medical College , Bengbu, Anhui, P. R. China .; 10. Department of Respiratory Medical Oncology , The Affiliated Cancer Hospital of Guangxi Medical University , Nanning, Guangxi Zhuang Autonomous Region, P. R. China .; 11. Department of Oncology , The Affiliated Hospital of Chengde Medical University , Chengde, Hebei, P. R. China .; 12. Department of Medical Oncology , Meizhou People’s Hospital , Meizhou, Guangdong, P. R. China .; 13. Department of Clinical Science , Xuanzhu Biopharmaceutical Co. Ltd. , Beijing, P. R. China .展开收起
FAQ
Cancer Communications审稿要多久?
截至2026-11-19,CrushSCI 只收录了 Cancer Communications 的 1 篇完整审稿记录:Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial,2026-03-02 收稿,2026-10-20 录用,审稿 232 天。只有一篇样本,结果仅供参考。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
